Giant pharmaceutical giant Gilead has announced that it had signed licensing deals with six generic drugmakers to produce and sell its human immunodeficiency virus (HIV) prevention medicine in lower-income countries.

Mia Malan, founder and editor-in-chief of Bhekisisa speaks to POWER Breakfast host Thabiso Tema about the pressure applied to overseas pharmaceuticals  to open lenacapavir to a patent pool that would allow generics to be sold under license in those countries.